Literature DB >> 21820877

Activity of ACHN-490 against meticillin-resistant Staphylococcus aureus (MRSA) isolates from patients in US hospitals.

Fred C Tenover1, Isabella Tickler, Eliana S Armstrong, Aya Kubo, Sara Lopez, David H Persing, George H Miller.   

Abstract

The activity of ACHN-490 was evaluated against 493 meticillin-resistant Staphylococcus aureus (MRSA) isolates collected in 2009-2010 from 23 US hospitals. The MIC(50) and MIC(90) values (minimal inhibitory concentrations for 50% and 90% of the organisms, respectively) for ACHN-490 were 1 and 2 μg/mL compared with 8 and 32 μg/mL for amikacin, 0.5 and 1 μg/mL for gentamicin and 2 and >16 μg/mL for tobramycin. The gene encoding the aminoglycoside-modifying enzyme APH(2″)-Ia/AAC(6')-Ie was present in 12% of the subset of 84 isolates examined by polymerase chain reaction (PCR), whilst the gene encoding ANT(4')-Ia was present in 89% of isolates. ACHN-490 activity was not affected by either enzyme.
Copyright © 2011 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21820877     DOI: 10.1016/j.ijantimicag.2011.05.016

Source DB:  PubMed          Journal:  Int J Antimicrob Agents        ISSN: 0924-8579            Impact factor:   5.283


  11 in total

Review 1.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

2.  A review of patents (2011-2015) towards combating resistance to and toxicity of aminoglycosides.

Authors:  Nishad Thamban Chandrika; Sylvie Garneau-Tsodikova
Journal:  Medchemcomm       Date:  2015-11-19       Impact factor: 3.597

3.  Biographical Feature: Fred C. Tenover, Ph.D., D(ABMM), F(AAM), FIDSA.

Authors:  Yi-Wei Tang
Journal:  J Clin Microbiol       Date:  2021-01-21       Impact factor: 5.948

4.  Characterization of nasal and blood culture isolates of methicillin-resistant Staphylococcus aureus from patients in United States Hospitals.

Authors:  Fred C Tenover; Isabella A Tickler; Richard V Goering; Barry N Kreiswirth; José R Mediavilla; David H Persing
Journal:  Antimicrob Agents Chemother       Date:  2011-12-12       Impact factor: 5.191

Review 5.  Strategies to overcome the action of aminoglycoside-modifying enzymes for treating resistant bacterial infections.

Authors:  Kristin J Labby; Sylvie Garneau-Tsodikova
Journal:  Future Med Chem       Date:  2013-07       Impact factor: 3.808

6.  Can Plazomicin Alone or in Combination Be a Therapeutic Option against Carbapenem-Resistant Acinetobacter baumannii?

Authors:  Cristina García-Salguero; Iciar Rodríguez-Avial; Juan J Picazo; Esther Culebras
Journal:  Antimicrob Agents Chemother       Date:  2015-07-13       Impact factor: 5.191

Review 7.  Plazomicin: A Novel Aminoglycoside for the Treatment of Resistant Gram-Negative Bacterial Infections.

Authors:  Khalid Eljaaly; Aisha Alharbi; Samah Alshehri; Jessica K Ortwine; Jason M Pogue
Journal:  Drugs       Date:  2019-02       Impact factor: 9.546

8.  In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.

Authors:  A Walkty; H Adam; M Baxter; A Denisuik; P Lagacé-Wiens; J A Karlowsky; D J Hoban; G G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2014-02-18       Impact factor: 5.191

9.  In Vitro Activity of Plazomicin against Gram-Negative and Gram-Positive Bacterial Pathogens Isolated from Patients in Canadian Hospitals from 2013 to 2017 as Part of the CANWARD Surveillance Study.

Authors:  Andrew Walkty; James A Karlowsky; Melanie R Baxter; Heather J Adam; George G Zhanel
Journal:  Antimicrob Agents Chemother       Date:  2018-12-21       Impact factor: 5.191

Review 10.  Breaking the Spell: Combating Multidrug Resistant 'Superbugs'.

Authors:  Shahper N Khan; Asad U Khan
Journal:  Front Microbiol       Date:  2016-02-18       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.